Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.sc

Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. “We achieved a significant milestone with the TOPAZ interim analysis proof-of-concept results. The data support apitegromab's p

Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress

Replimune Group Inc

Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.

2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the closing of its underwritten public offering of 3,717,948 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,179,487 shares of its common stock at an exercise price of $0.0001 per share. The shares

Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share. In addition, in lieu of common stock to certain investors, Scholar Rock is offering pre-funded warrants to purchase 2,1

Scholar Rock Announces Pricing of Public Offering of Common Stock and Prefunded Warrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it intends to offer and sell in an underwritten public offering $150,000,000 of shares of its common stock. In addition, Scholar Rock intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common s

Scholar Rock Announces Proposed Public Offering of Common Stock

Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.

Why Scholar Rock Stock Is Skyrocketing Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive six-month interim analysis results from the TOPAZ Phase 2 clinical trial. Treatment with SRK-015 led to improvements in Hammersmith scale scores (primary efficacy endpoint) in all three cohorts of patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA). Dose

Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the closing of a $50 million debt facility with Silicon Valley Bank and Oxford Finance LLC, of which the first $25 million was funded at closing. Scholar Rock intends to use the proceeds for general corporate purposes, including the advancement of the Company's pipeline and

Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance

Scholar Rock Holding Corp. (SRRK) CEO Tony Kingsley on Q2 2020 Results - Earnings Call Transcript

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -22.64% and -40.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the second quarter ended June 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs.

Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 9:45 am ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.schola

Scholar Rock to Present at the 2020 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it will host a live conference call and webcast at 8:00am ET on Friday, August 7, 2020 to discuss second quarter 2020 financial results and business progress, as well as provide an introduction to the newest members of its management team.

Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Edward (Ted) Myles, as Chief Financial Officer and Head of Business Operations, responsible for finance, investor relations, corporate communications, IT and facilities.

Scholar Rock Appoints Edward (Ted) Myles as Chief Financial Officer and Head of Business Operations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tony Kingsley as president and chief executive officer, effective August 1, 2020. Mr. Kingsley, who was appointed to Scholar Rock’s Board of Directors in May, replaces Nagesh K. Mahanthappa, Ph.D., MBA, who has chosen to step down after serving in this ro

Scholar Rock Appoints Tony Kingsley as President and CEO

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scholar Rock Holding Corporation (SRRK) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.

Scholar Rock Sees Hammer Chart Pattern: Time to Buy?

Is  (SRRK) Outperforming Other Medical Stocks This Year?

Is Scholar Rock Holding (SRRK) Stock Outpacing Its Medical Peers This Year?

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Tops Revenue Estimates

-  Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy

Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020

CAMBRIDGE, Mass., Dec.  19, 2019  (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2019.

Scholar Rock Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Nov.  19, 2019  (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results from the TOPAZ Phase 2 proof-of-concept trial of  SRK-015  for the treatment of patients with spinal muscular atrophy (SMA).  The planned preliminary PK/PD analysis, which includes data from 29 patients with SMA across all three cohorts, showed dose-proportional drug exposure and demonstrated target engagement, as evidenced by dose-dependent increases of up to 100-fold in the serum levels of latent myostatin following SRK-015 treatment (2 mg/kg and 20 mg/kg doses).  SRK-015 is a highly selective inhibitor of the precursor, or latent form, of myostatin, and was specifically designed to avoid interactions with related targets such as activins, GDF-11, or BMPs, to potentially improve the therapeutic profile compared to traditional non-selective inhibitors.

Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates

Fluidigm

Falling knives are stocks whose share price has fallen more than 59% over the past year, drawing interest from investors as these securities can deliver huge rewards if they rebound.

News for Scholar Rock Holding Corp Stock (SRRK)